Journal of Cutaneous Immunology and Allergy (Dec 2021)

Possible activation of effector B cells during drug‐induced hypersensitivity syndrome

  • Yutaka Matsumura,
  • Rei Watanabe,
  • Yasuko Niijima,
  • Haruka Kawakita,
  • Junichi Furuta,
  • Yoshiyuki Nakamura,
  • Yosuke Ishitsuka,
  • Naoko Okiyama,
  • Yasuhiro Fujisawa,
  • Manabu Fujimoto

DOI
https://doi.org/10.1002/cia2.12191
Journal volume & issue
Vol. 4, no. 6
pp. 166 – 169

Abstract

Read online

Abstract Although the development of autoimmune disorders is recognized in drug‐induced hypersensitivity syndrome (DIHS), the serial change of B‐cell activity has not been well‐addressed. Herein, the serum levels of IL‐6, IL‐10, B‐cell activating factor of the tumor necrosis factor family (BAFF), and a proliferation‐inducing ligand (APRIL) in three DIHS patients were tracked over time. While IL‐6 and IL‐10 tended to be elevated according to the disease activity, BAFF and APRIL increased during the improved phase. Our results imply that the continuous activation of B cells may be involved in the prolonged disease activity of DIHS and the development of autoimmune disorders.

Keywords